Podcasts about Medicine

After decades of stagnation and caution, the FDA is radically changing their advice on hormone replacement therapy for menopausal women. We speak to the FDA Commissioner about the new advice for women. Get the facts first with Morning Wire. Chevron: Build a brighter future right here at home. Visit https://Chevron.com/America to discover more. HelloFresh: Go to https://HelloFresh.com/MORNINGWIRE10FM now to Get 10 Free Meals + a Free Item for Life! - - - Wake up with new Morning Wire merch: https://bit.ly/4lIubt3 - - -Privacy Policy: https://www.dailywire.com/privacy Learn more about your ad choices. Visit podcastchoices.com/adchoices

Is homeopathy a gentle natural cure… or just really confident sugar pills? This week on Hysteria 51 Kevin Crispin of the Behind Beautiful Things podcast joins us as we dive into the strange world of “like cures like,” ultra-dilutions, and remedies so watered down they make LaCroix look concentrated. From onion pills for allergies to ghostly duck-liver flu treatments, we break down how homeopathy works, why people swear by it, and how it can turn downright dangerous when it replaces real medical care.We'll explore the bizarre history of homeopathy, its modern comeback as “alternative medicine,” and the very real harm when serious conditions get treated with nothing more than placebo pellets and good vibes. But we're also turning a skeptical eye on the U.S. healthcare system itself—because when seeing a real doctor costs a small mortgage payment, it's no wonder people reach for magic water. Tune in for jokes, science, and just enough rage to dilute your faith in everyone equally.Special thanks to this week's research sources:WebsitesArizona Homeopathic - https://arizonahomeopathic.org/homeopathy-and-covid-19/ Discover Homeopathy - https://www.discoverhomeopathy.co.uk/victims/ Science Based Medicine - https://sciencebasedmedicine.org/belief-in-homeopathy-results-in-the-death-of-a-7-year-old-italian-child/ Springer - https://link.springer.com/article/10.1007/s00508-020-01624-x Scientific American - https://www.scientificamerican.com/article/hundreds-of-babies-harmed-by-homeopathic-remedies-families-say/ Perth Now - https://www.perthnow.com.au/news/cancer-victim-penelope-dingle-in-awe-of-homeopath---husband-ng-7c51c3e2f263eb5e4e530d5cb0a8b152 National Library of Medicine - https://pmc.ncbi.nlm.nih.gov/articles/PMC7253376/ National Library of Medicine - https://pmc.ncbi.nlm.nih.gov/articles/PMC1676328/Email us your favorite WEIRD news stories:weird@hysteria51.com Support the ShowGet exclusive content & perks as well as an ad and sponsor free experienceat https://www.patreon.com/Hysteria51 from just $1 ShopBe the Best Dressed at your Cult Meeting!https://www.teepublic.com/stores/hysteria51?ref_id=9022See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week we review the topic of mitral annular disjunction ("MAD") and the possible association with ventricular arrhythmia or sudden death in the connective tissue disease patient. Is there a 'cut off' distance above which patients deserve more significant arrhythmia surveillance? What is the best way to measure the MAD distance? Can patients with low MAD distances have lower degrees or even no arrhythmic surveillance? How often should this distance be measured on CMR and can an echo measurement provide similar data? Dr. Daniel Castellanos, the first author of this work and Assistant Professor of Pediatrics at Harvard Medical School shares his deep insights this week.DOI: 10.1016/j.jocmr.2025.101954

Steve Gruber talks with Peter Pitts, former Associate FDA Commissioner and President of the Center for Medicine in the Public Interest (CMPI), about rising healthcare costs and the recent Senate Finance hearing. They dive into how hospitals set prices, why healthcare costs continue to escalate, and what policymakers are debating to bring more transparency and accountability to the system. Pitts provides an insider's perspective on the intersection of healthcare policy, pricing, and patient impact.

What if your erection could tell you something deeper about your health—something even your doctor might miss?In this exclusive episode, Dr. Arthur Burnett, one of the leading experts in urology and a key figure in the science behind Viagra, joins the conversation. Together, we explore the real connection between erectile dysfunction, prostate cancer, and overall prostate health. We dive into what's fact, what's fiction, and why ED might be your body's first warning sign of something much bigger. Whether you're dealing with performance issues or concerned about your prostate, this episode is for you.Hit play now. Your health, and your future, may depend on it.--------------About Dr. Arthur BurnettDr. Arthur Burnett is a world-renowned urologist and professor at the Johns Hopkins School of Medicine, where he holds the prestigious Patrick C. Walsh Professorship in Urology. As Director of the Male Consultation Clinic and Vice Chair for faculty development at the James Buchanan Brady Urological Institute, he brings decades of groundbreaking expertise in erectile dysfunction, prostate cancer, and reconstructive urology.A pioneer in the discovery of nitric oxide's role in erections, Dr. Burnett's research was instrumental in the development of Viagra. He has performed over 3,000 nerve-sparing radical prostatectomies and authored more than 500 peer-reviewed publications. With honors from the NIH, FDA, and the American Urological Association, Dr. Burnett continues to lead the field in advancing male sexual and prostate health.Want to connect with Dr. Arthur Burnett? Visit the Johns Hopkins Urology website or find his books on Amazon to learn more about his work in men's health.--------------Resources mentioned:Modern Man CribMediterranean DietGood Morning Wood Smoothie--------------Curious about how you can boost your bedroom game and build lasting confidence? Check out the course at getwoodnow.com and start your journey to feeling like yourself again!--------------If you enjoyed this episode and want to learn more and get more tips, subscribe to The Modern Man newsletter for exclusive content delivered straight to your inbox! https://dranne.co/themodernman--------------Follow Me On:InstagramTwitterFacebookTikTokYouTube--------------For all links and resources mentioned on the show and where to subscribe to the podcast, please visit

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Harry P. Erba, MD, PhD, about the FDA approval of ziftomenib (Komzifti) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Dr Erba is a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine at the Duke University School of Medicine, as well as director of the Leukemia Program and director of Phase I Development in Hematologic Malignancies. He is also a member of the Duke Cancer Institute in Durham, North Carolina. In our exclusive interview, Dr Erba discussed the significance of this approval, key efficacy and safety findings from the pivotal phase 1/2 KOMET-001 trial (NCT04067336), and the role ziftomenib may play throughout the evolution of the AML treatment paradigm. _____ That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air. *OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn. This content is a production of OncLive; this OncLive On Air podcast is supported by funding, however, content is produced and independently developed by OncLive.

Episode 206: Street Medicine and Harm Reduction.  Mohammed Wase (medical student) and Dr. Singh describe what it is like to provide health care on the streets. They share their personal experiences working in a street medicine team. They describe the practice of harm reduction and emphasize the importance of respecting autonomy and being adaptable in street medicine. Written by Mohamed Wase, MSIV, American University of the Caribbean. Editing by Hector Arreaza, MD. Hosted by Harnek Singh, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Introduction Dr. Singh: Welcome to another episode of our podcast, my name is Dr. Harnek Singh, faculty in the Rio Bravo Family Medicine Residency Program. Today we have prepared a great episode about street medicine, a field that has grown a lot during the last decade and continues to grow now. We are joined by a guest who is passionate about this topic. Wase, please introduce yourself.Wase: Hello everyone, my name is Mohammed, many know me as Wasé, I am a 4th year medical student from the American University of the Caribbean. Today we're diving into a topic that sits at the intersection of medicine, compassion, and public health — Street Medicine and Harm Reduction. We're going to step outside with this episode, literally, away from the clinic and hospital, to explore more about what care looks like in the streets. Historic background: How did street medicine start?Wase: The roots of Street Medicine in the United States go back to Dr. Jim Withers in Pittsburgh in the 1990s, who literally began by dressing as a homeless person and providing care on the streets to build trust. His efforts have shaped street medicine to what it is today. It combines primary care, mental health, and social support. Dr. Singh: For family physicians, this model aligns perfectly with our holistic approach. We don't just treat diseases; we treat people in context — their environment, their challenges, their stories. What is the main population seen by a street medicine team?Wase: This patient population includes those struggling with homelessness, housing insecurity, food insecurity, substance use disorders; with patients being preoccupied on where they will sleep that night or when their next meal comes, they do not have the luxury of prioritizing their health. Street Medicine is a powerful outreach program to bring care to them in order to provide equitable care within our community. Dr. Singh: How is street medicine different than caring for patients in the clinic?Wase: Working on the street means we have to think differently about what healthcare looks like — and that's whereharm reductioncomes in.What is Harm Reduction?Wase: Harm reduction is a public health philosophy that focuses on reducing the negative consequences of high-risk behaviors, rather than demanding complete abstinence.Dr. Singh: Preventive care is the backbone of family medicine. For example, we keep up with the USPSTF guidelines and make sure our patients are up to date with their screenings. But what does that look like in the street medicine setting? Wase: In practice, that might mean:-needle exchange program: Offering clean syringes to prevent HIV transmission and removing used needles-distributing naloxone to prevent overdose deaths-offering fentanyl test-strips to prevent use of substances that are unknowingly laced with fentanylDr. Singh: Also:-providing condoms to prevent sexually transmitted infections-providing wound care to prevent further spread of infectionWase: Yes, the idea is: people are going to engage in risky behaviors whether or not we approve of it, so let's meet them with compassion, tools, and trust instead of judgment. Harm reduction also applies beyond substance use; think about safer sex education, or even diabetic foot care among people who can't refrigerate insulin or change shoes daily. It's all about meeting people where they areandkeeping them alive and engaged in care. Planning in Street Medicine: Wase: It takes careful disposition planning and aftercare for this population. Instead of the traditional outpatient setting where we can place referrals and expect our patients to follow through with them. On street medicine, for follow up visits it requires arranging transportation, finding a pharmacy close in proximity, educating and counseling on medication adherence and how to make it, and making sure they have some sort of shelter to get by. Dr. Singh: Let's describe a typical street med encounter.Wase: A typical Street Medicine encounter might look like this: a small team — usually a physician, nurse, social worker, and sometimes a peer advocate — goes out with backpacks of supplies. They might start with wound care, blood pressure checks, or even medication refills. But what's just as important is the relationship-building. Sometimes, the first visit isn't about medicine at all — it's about showing up consistently.Over time, that trust opens the door for conversations about addiction treatment, mental health, and preventive care. For example, in some California Street Medicine programs, teams are treating chronic conditions like hypertension, diabetes, and hepatitis C, right where patients live with the same evidence-based care we'd give in a clinic. One of my favorite quotes from Street Medicine teams is: “We're not bringing people to healthcare; we're bringing healthcare to people.”Challenges in Street Medicine:Wase: The populations that you will encounter include many people who will often downplay their own health concerns and prior diagnoses. Unfortunately, this is usually from countless months or years of feeling neglected by our healthcare system. Some may even express distrust in our healthcare system and healthcare providers. Patient will, at times, be apprehensive to receive care or trust you enough to tell their story. Dr. Singh: Interviewing patients is a critical aspect of providing equitable care on the streets. It is always important to offer support and medical care, even if the patient denies it, always reassure that your street medicine clinic will be around every week and ready for them when they would like to seek care. Wase: Respecting patient autonomy is an utmost concern as well. Another element of interviewing to consider is to invite new ideas and information; instead of lecturing patients about taking medications on time or telling them they need to stop doing drugs—simply asking a patient “would you like to know more about how we can help you stop using opioids?” respects their choice but can also spark new ideas for them to consider. Singh: Adaptability is another key component to exceling patient care in street medicine. Like, performing physical exams on park benches or in the back of a minivan. Always doing good with our care but also respecting their autonomy is crucial in building a trust that these patients once lost with our system. Wase: Each patient has their own timeline, but we as providers should always assure them that our door is always open for them when they are ready to seek care. Conclusion.Wase: So, to wrap up — Street Medicine and harm reduction remind us that healthcare isn't just about hospitals and clinics. It's about relationships, trust, and dignity.Every patient deserves care, no matter where they sleep at night.If you're a resident or student listening, I encourage you to seek out these experiences — volunteer with Street Medicine teams, learn from harm reduction workers, and let it shape how you practice medicine. Thank you for listening to this episode of the Rio Bravo qWeek podcast. I'm Mohammed — and I hope this conversation inspires you to meet patients where they are and walk with them on their journey to health.Dr. Singh: If you liked this episode, share it with a friend or a colleague. This is Dr. Singh, signing off.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Doohan, N.C. “Street Medicine: Creating a ‘Classroom Without Walls' for People Experiencing Homelessness.” PMC – National Library of Medicine, 2019.Hawk, M., et al. “Harm Reduction Principles for Healthcare Settings.” Harm Reduction Journal, vol. 14, no. 1, 2017.Withers, J.S. “Bringing Health Professions Education to Patients on the Streets.” Journal of Ethics, AMA, vol. 23, no. 11, Nov. 2021.“Our Story.” Street Medicine Institute, 2025, www.streetmedicine.org/our-story.“Principles of Harm Reduction.” National Harm Reduction Coalition, 2024, https://harmreduction.org/about-us/principles-of-harm-reduction/.Salisbury-Afshar, Elizabeth, Bryan Gale, and Sarah Mossburg. “Harm Reduction Strategies to Improve Safety for People Who Use Substances.” PSNet, Agency for Healthcare Research & Quality, 30 Oct. 2024.Douglass, A.R. “Exploring the Harm Reduction Paradigm: The Role of Boards in Drug Policy and Practice.” PMC – National Library of Medicine, 2024.Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

In this episode, Guy engaged in a fascinating conversation with Bruce H. Lipton, the author of 'Biology of Belief'. They discussed the chaotic state of the world and how it mirrors the internal chaos within humans. Bruce emphasized the importance of awakening to thrive into the future and explains how the subconscious mind and environmental factors influence our lives. They explored concepts from quantum physics and epigenetics, delving into how our consciousness shapes our reality. Bruce shared insights on breaking free from limiting beliefs and underscores the importance of mindful living. The discussion also touched on the role of pharmaceutical companies, energy medicine, and the global state of affairs, emphasizing the need for a transformative shift towards cooperation and self-awareness. About Bruce: Bruce H. Lipton, Ph.D., a pioneer in the new biology, is an internationally recognized leader in bridging science and spirit. A cell biologist by training, Bruce was on the faculty of the University of Wisconsin's School of Medicine and later performed ground-breaking stem cell research at Stanford University.  He is the best‐selling author of The Biology of Belief and the more recent Spontaneous Evolution, co‐authored with Steve Bhaerman. Bruce received the 2009 prestigious Goi Peace Award (Japan) in honor of his scientific contribution to world harmony and more recently in 2012 was chosen as Peace Ambassador for the "Thousand Peace Flags" project of the Argentinian Mil Milenios de Paz. Key Points Discussed:  (00:00) - They Want You to Stay Small — Here's How to Rewrite Your Reality! (00:44) - Welcome to the Podcast with Guy Lawrence (01:38) - Bruce Lipton's Journey and the Impact of 'Biology of Belief' (02:30) - The Science of Consciousness and Epigenetics (05:36) - The Disconnect Between Conscious and Subconscious Minds (16:13) - The Power of Love and Mindfulness (22:49) - The State of the World and Human Civilization (27:14) - The Metamorphosis of Human Civilization (32:36) - The Role of Fear and Cooperation in Evolution (35:38) - Understanding and Changing Your Programming (37:53) - Understanding the Creator Within (38:03) - The Conscious vs. Subconscious Mind (38:37) - The Power of Programming (40:32) - Methods to Reprogram the Subconscious (42:18) - Energy Psychology and Super Learning (46:00) - The Influence of Quantum Physics (46:47) - Critique of the Pharmaceutical Industry (53:47) - The Role of Stress and Fear (55:46) - Personal Practices for a Better Life (59:49) - Final Thoughts and Reflections How to Contact Bruce Lipton:www.brucelipton.com   About me:My Instagram: www.instagram.com/guyhlawrence/?hl=en Guy's websites:www.guylawrence.com.au www.liveinflow.co''

Fear of virologic failure is a major barrier to ensuring that people living with virally suppressed HIV are receiving the most optimal antiretroviral therapy (ART) regimen for them. Stream this Medical Minute to learn more about key guideline recommendations regarding ART switch and reassuring clinical data regarding efficacy, tolerability, and quality of life associated with switching a suppressive ART regimen. Topics covered include:Efficacy of switching to 2-drug oral ART: real-world evidenceReal-world analyses of virologic failure with switch to long-acting cabotegravir plus rilpivirinePatient selection to reduce risk of virologic failure with switch Regimen-specific switch considerationsPresenters:Dima Dandachi, MD, MPH, FIDSA, FACPAssociate Professor of MedicineDivision of Infectious DiseasesUniversity of MissouriMedical DirectorHIV Treatment and Prevention Program, MUHCMedical DirectorBoone County Public Health and Human ServicesColumbia, MissouriChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationQueen Mary University of LondonFaculty of Medicine and DentistryHonorary Consultant PhysicianBarts Health NHS TrustLondon, United KingdomLink to full program and accompanying slides:https://bit.ly/3KPN0xbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

You can send and text and we love them.. but apparently we cant respond. Sorry!!A daily dose of good news in two minutes time... give or takeSupport the showJoin us on Facebook https://www.facebook.com/groups/awesomenewsdailyor email me at awesomenewsdaily@gmail.com

Far from a future add-on, artificial intelligence is already embedded in the cycle of drug safety, from case processing to signal detection. Versatile generative AI models have raised the bar of possibilities but also increased the stakes. How do we use them without losing trust and where do we set the limits?In this two-part episode, Niklas Norén, head of Research at Uppsala Monitoring Centre, unpacks how artificial intelligence can add value to pharmacovigilance and where it should – or shouldn't – go next.Tune in to find out:How to keep up with rapid developments in AI technologyWhy model and performance transparency both matterHow to protect sensitive patient data when using AIWant to know more?Listen to the first part of the interview here.In May 2025, the CIOMS Working Group XIV drafted guidelines for the use of AI in pharmacovigilance. The draft report received more than a thousand comments during public consultation and is now being finalised.Earlier this year, the World Health Organization issued guidance on large multi-modal models – a type of generative AI – when used in healthcare.Niklas has spoken extensively on the potential and risks of AI in pharmacovigilance, including in this presentation at the University of Verona and in this Uppsala Reports article.Other recent UMC publications cited in the interview or relevant to the topic include:a pre-print on the revised vigiMatch algorithm for duplicate detectionan article on the pitfalls of disproportionality analysisa pre-print on critically appraising AI applications for rare-event recognitionFor more on the ‘black box' issue and maintaining trust in AI, revisit this interview with GSK's Michael Glaser from the Drug Safety Matters archive. Join the conversation on social mediaFollow us on Facebook, LinkedIn, X, or Bluesky and share your thoughts about the show with the hashtag #DrugSafetyMatters.Got a story to share?We're always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!About UMCRead more about Uppsala Monitoring Centre and how we promote safer use of medicines and vaccines for everyone everywhere.

Clinical trial design in nephrology is evolving. In this episode, leading experts explore why a paradigm shift is needed from traditional biomarkers to patient-centered outcomes and practical strategies for advancing trial implementation. This conversation draws on insights from the ISN Consensus Meeting on Changing Paradigms of Studies in CKD (Vancouver, Nov 22-23, 2024) where clinicians, trialists, patient partners, regulators and industry scientists came together to rethink trial endpoints, outcomes and designs. Together, they discuss how reimagining kidney trials can generate more relevant, equitable, and actionable evidence for better kidney care worldwide. ParticipantsAdeera Levin Professor of Medicine, University of British Columbia, Canada, and Past-President of the International Society of Nephrology (ISN). Dr. Levin is a global leader in kidney health research, with extensive experience in chronic kidney disease (CKD) management, clinical trials, and international health system strengthening. Jennifer Lees Senior Clinical Lecturer and Honorary Consultant Nephrologist at the University of Glasgow, UK. Dr. Lees' research focuses on improving patient outcomes in kidney disease through better trial design, biomarker evaluation, and translational approaches linking research to clinical care. Kevin Weinfurt Professor and Vice Chair of Faculty, Department of Population Health Sciences, Duke University School of Medicine, USA. Dr. Weinfurt is a behavioural scientist specializing in patient-reported outcomes (PROMs), ethical aspects of research participation, and improving the relevance of clinical trials to patients lived experiences. Hiddo J. Lambers Heerspink Professor of Clinical Trials and Personalized Medicine, University Medical Center Groningen, The Netherlands. Dr. Heerspink's work bridges pharmacology, nephrology, and precision medicine, focusing on optimizing kidney and cardiovascular outcomes through innovative clinical trial design and biomarker discovery. To read more, explore the related paper Changing Paradigms of Studies in Kidney Diseases published in Kidney International.

In this episode, Dr. Paul Wheatley-Price is back for our annual recap of the IASLC 2025 World Conference on Lung Cancer (WCLC), which took place in Barcelona, Spain in early September. He is joined by two special guests, Dr. Barbara Melosky, Professor of Medicine at UBC and Medical Oncologist at BC Cancer, and Dr. Peter Ellis, Professor of Oncology at McMaster University and Medical Oncologist at Juravinski Cancer Center. They chat about all the updates for treatments like osimertinib for EGFR+ lung cancer, immunotherapy for small-cell lung cancer, and promising new treatments like for HER2 and ADCs coming down the pipeline.

Welcome to Episode #32: Has Medicine Lost Its Mind? featuring Dr. Robert Smith, award-winning educator and author. In this eye-opening conversation, Dr. Smith joins Kirsten to uncover how medicine has lost touch with the mind-body connection and how a path to repair is right at our fingertips. They explore the realities of outdated training, misdiagnosis, and fragmented care, whilst highlighting how evidence-based, patient-centered methods can transform the way doctors approach mental health. Drawing on decades of clinical experience, Dr. Smith shares a bold roadmap for reform and explains why integrating the biopsychosocial model isn't just hopeful—it's urgent. Together, Kirsten and Dr. Smith discuss what the public and policymakers can do now, how whistleblowers are driving progress, and why we're at a pivotal moment in history for reshaping the future of medicine.

Show NotesStory 1: Computing and AITitle: Scientists create world's first microwave-powered computer chip — it's much faster and consumes less power than conventional CPUsSource: LiveScience.comLinks:LiveScience ArticleResearch PaperCornell Chronicle PostingStory 2: Sustainable MaterialsTitle: Green alternative for light-emitting materials in displays uses plant waste and amino acidsSource: TechXplore.comLinks:TechXplore ArticleResearch PaperStory 3: Next-Gen ArmorTitle: Scientists Created a Bulletproof Material 3 Times Stronger Than Kevlar—It's Already Breaking RecordsSource: Popular MechanicsLinks:Popular Mechanics ArticleResearch PaperNew Scientist ArticleStory 4: Medical TechTitle: Injectable antenna could safely power deep-tissue medical implantsSource: MIT Media LabLink: MIT News ArticleHonorable MentionsTitle: Tabletop particle accelerator could transform medicine and materials scienceSource: Phys.orgLink: Phys.org ArticleTitle: Need a New 3D Material? Build It With DNASource: Columbia University EngineeringLink: Columbia Engineering ArticleTitle: Spider-Like Robot Combines 3D Printing and Construction for Earth and Lunar ApplicationsSource: 3Dprinting.comLink: 3Dprinting.com ArticleTitle: Robots you can wear like clothes: Automatic weaving of 'fabric muscle' brings commercialization closerSource: TechXplore.comLink: TechXplore Article

Full Show Notes: https://bengreenfieldlife.com/drandrew Dr. Andrew Koutnik is a research scientist whose career bridges cutting-edge science, elite performance, and personal experience living with type 1 diabetes for over 17 years. His work focuses on how nutrition, metabolism, and lifestyle can be leveraged to maximize human health, performance, and resilience across diverse conditions—from chronic disease to extreme environments. Dr. Andrew Koutnik earned his Ph.D. in Medical Sciences (Molecular Pharmacology and Physiology) from the University of South Florida Morsani College of Medicine. Prior to joining FSU, Dr. Andrew Koutnik served as a Faculty/Principal Investigator at Sansum Diabetes Research Institute and Florida Institute for Human and Machine Cognition. His research has spanned over $70,000,000 in research funding, including NASA missions, U.S. Special Operations Command, Defense Advanced Research Projects, Office of Naval Research, Department of Defense, and NIH-funded clinical trials Episode Sponsors: LVLUP Health: I trust and recommend LVLUP Health for your peptide needs as they third-party test every single batch of their peptides to ensure you’re getting exactly what you pay for and the results you’re after! Head over to lvluphealth.com/BGL and use code BEN15 for a special discount on their game-changing range of products. Ketone-IQ: Ketones are a uniquely powerful macronutrient that can cross the blood-brain barrier and increase brain energy and efficiency. With a daily dose of Ketone-IQ, you'll notice a radical boost in focus, endurance, and performance. Save 30% off your first subscription order of Ketone-IQ at Ketone.com/BENG. CAROL Bike: The science is clear—CAROL Bike is your ticket to a healthier, more vibrant life. And for a limited time, you can get $100 off yours with the code BEN. Don't wait any longer, join over 25,000 riders and visit carolbike.com/ben today. Sunlighten: Sunlighten's patented infrared sauna technology delivers the highest quality near, mid, and far infrared wavelengths to reduce inflammation, boost mitochondrial function, enhance detox pathways, and optimize recovery—backed by 25+ years of clinically proven, non-toxic innovation. Save up to $1,400 at Sunlighten.com/BEN with code BEN. Gameday Men’s Health: Gameday Men's Health offers science-backed, physician-led men's health optimization with personalized protocols for testosterone, peptide therapy, ED treatment, and more—helping you perform at your best whether you're training hard or keeping up with life. Visit gamedaymenshealth.com/bengreenfield for a free testosterone test and consultation at a clinic near you. Boundless Bar: If you’re ready to fuel workouts, sharpen your focus, and support whole-body vitality, grab your Boundless Bars now at boundlessbar.com —and save 10% when you sign up for a Boundless Bar subscription.See omnystudio.com/listener for privacy information.

James Kimmel, Jr., PhD, is an assistant clinical professor of psychiatry at the Yale School of Medicine and the author of The Science of Revenge. He’s known in part for identifying compulsive revenge seeking as an addiction. He explains how perceived wrongs, grievances, and revenge desires—and how we deal with them, or not—affect us all. Actually trying to get revenge is pretty much always a lost cause—it simply makes us feel worse—but often, blanket forgiveness feels impossible. Which is why Kimmel came up with a simple but brilliant process that you can run through in the courtroom of your mind. For the show notes, head to my Substack.See omnystudio.com/listener for privacy information.

About this episode: As hesitancy about human vaccines rises, so too does skepticism of routine pet immunizations. In this episode: Veterinarians Meghan Davis and Kaitlin Waite explain what's behind growing anti-vaccine sentiment among pet owners, how veterinarians are navigating this divide, and why an understanding of the human-animal bond can yield better public health outcomes for all. Guests: Meghan Davis, PhD, MPH, DVM, is a veterinarian and public health researcher at the Johns Hopkins Bloomberg School of Public Health with a joint appointment at the School of Medicine. Kaitlin Waite, MPH, DVM, is a veterinarian and a postdoctoral fellow at the Johns Hopkins Bloomberg School of Public Health, where she also serves as the Deputy Director of Outreach Core at the POE Center. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content: Here's Why Fewer People Are Vaccinating Their Pets—TIME Vaccine Skepticism Comes for Pet Owners, Too—New York Times The importance of vaccinating your pet—Virginia-Maryland College of Veterinary Medicine Could One Health Prevent the Next Pandemic?—Public Health On Call (September 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Is it just an eczema (atopic dermatitis) flare or could it be something else? Most people don't realize that Staph aureus could be the hidden skin flare trigger that actively weakens your skin barrier, triggering more inflammation, itchiness, and persistent eczema symptoms. Even if it seems “normal,” the presence of Staph might point to deeper imbalances that need attention.In this episode, we dig into how Staph aureus, the gut microbiome, environmental toxins, and even air pollution can all contribute to recurring eczema.Joining me is Dr. Peter Lio, a board-certified dermatologist and respected voice in integrative dermatology. He's a Clinical Assistant Professor at Northwestern University and has authored over 100 papers, along with a textbook on Integrative Dermatology.If you're ready to understand why your eczema isn't clearing up, this is a must-listen conversation filled with insight and practical takeaways.⭐️Mentioned in This Episode:- Learn how to address your Eczema root causes

Recently, leucovorin and acetaminophen have been at the center of new discussions in pediatric medicine. Could leucovorin really help some children with autism? Does the latest evidence suggest acetaminophen has any impact on neurodevelopment? In today's episode, we'll break down what the science actually tells us, what remains uncertain and how pediatricians can confidently guide families through these complex topics. Joining us for this important discussion is Abigail Angulo, MD. She is a developmental-behavioral pediatrician at Children's Hospital Colorado. She is also an associate professor at the University of Colorado School of Medicine. Some highlights from this episode include:  The science behind autism  The role of Tylenol in pregnancy and newborn development  What leucovorin is used for and when it should be prescribed  How to navigate difficult conversations with families who expect certain outcomes For more information on Children's Colorado, visit: childrenscolorado.org. 

On Food Talk with Dani Nierenberg, Dani speaks with Dr. Christina Economos, Dean of the Friedman School of Nutrition Science and Policy at Tufts University. They talk about democratizing food and nutrition education, the community-led Food is Medicine research the Friedman School is advancing in the Mississippi Delta, and creating pathways for the next generation of leaders working to improve food, nutrition, and public health systems. While you're listening, subscribe, rate, and review the show; it would mean the world to us to have your feedback. You can listen to "Food Talk with Dani Nierenberg" wherever you consume your podcasts.

Even on the best days in medicine, it can feel like there just aren't enough hours to get everything done. Between charting, follow-ups, messages, and the endless stream of “urgent” things… it's easy to lose your rhythm.In this episode, Tracy shares her favorite touchstones—small, intentional habits and micro-moments that help clinicians stay grounded, focused, and calm even in the middle of chaos.You'll hear about the origin of the term “touchstone” (yes, it comes from testing the purity of gold!) and learn how to apply that metaphor to your day as a way to test your focus, presence, and peace.From morning momentum to mid-day resets and evening recovery, Tracy walks through simple, actionable ways to bring rhythm back to your clinical days—so you can feel less scattered and more steady, even when the day goes sideways.✨ You'll learn:The science and symbolism behind touchstonesSimple ways to build morning momentum that lastsHow to use handwashing, breathing, and movement as energy resetsSystems for charting, batching, and time-blocking that reduce overwhelmWhy boundaries are essential for focus and sustainabilityHow to create transition rituals to leave work at work

Nitric oxide touches nearly every system that keeps us alive, yet it's one of the first things to decline with age.  In this episode, I sit down with my friend Dr. Nathan Bryan to uncover how low nitric oxide affects blood pressure, circulation, metabolism, sexual performance, and even the microbiome on your skin and in your mouth. We get real about the everyday habits silently blocking this molecule, like mouthwash, fluoride, antacids, sugar, and an over-sterilized environment. We also talk about what restoring nitric oxide can do for your energy, clarity, stamina, and long-term health.   "There's only two people in the world who need nitric oxide. There's the people who are sick and wanna get well, and there's the people who are well and don't wanna get sick." ~ Dr. Nathan Bryan   In This Episode: - What is nitric oxide? - Why Viagra doesn't work for 50% of men - Ways to increase nitric oxide - Symptoms of nitric oxide deficiency - The age related decline in nitric oxide production - How heavy metals and toxins scavenge nitric oxide - How to naturally restore nitric oxide - Dr. Bryan's nitric oxide lozenge and skincare - The problem with beets, and oxalates in vegetables  - How often to take nitric oxide lozenge   Products & Resources Mentioned: N1O1 Nitric Oxide Supplements: Lower pressure, sharper energy, youthful glow. Shop at https://n1o1.com   Puori PW1 Whey Protein & Creatine+: Head to https://puori.com/wendy and use code WENDY for 20% off, even on subscriptions. Organifi Collagen: Grab 20% off with code MYERSDETOX at https://organifi.com/myersdetox  TruEnergy Lip Peptide Treatment: Buy one, get one free for listeners at https://trytruenergy.com/wendy3  Chef's Foundry P600 Cookware: Get an exclusive discount at https://bitly/myersdetox  Heavy Metals Quiz: Take it at https://heavymetalsquiz.com    About Nathan Bryan: Dr. Nathan Bryan is a global leader in nitric oxide research with more than 25 years of groundbreaking work in the field. He earned his Bachelor of Science in biochemistry from UT Austin and completed his PhD at Louisiana State University School of Medicine before continuing postdoctoral research at Boston University School of Medicine. His discoveries have shaped much of what we now understand about nitric oxide, cardiovascular health, and metabolic function. Nathan is the founder and CEO of Bryan Therapeutics, a clinical-stage biotechnology company developing nitric-oxide-based therapies for heart disease, Alzheimer's, and chronic wounds. He is also the creator of the N101 nitric oxide product line and a passionate educator dedicated to helping people restore their levels of this vital molecule for better health and longevity. Learn more at https://n101.com    Disclaimer The Myers Detox Podcast was created and hosted by Dr. Wendy Myers. This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast, including Wendy Myers and the producers, disclaims responsibility for any possible adverse effects from using the information contained herein. The opinions of guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guests' qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.

Learn More About Dr. Gina Williams at: https://www.facebook.com/share/xPBoeiz4gzhJGB4L/?mibextid=qi2Omghttps://youtube.com/@drgina_dpt?si=rmiLiZKl0a3wmb5s Listen to her podcast at: https://youtube.com/@drgina_dpt?si=rmiLiZKl0a3wmb5s Show notes:

StartUp Health community member Victor Penev, CEO & Founder of Edamam, joins Unity Stoakes to talk about how AI is accelerating the Food as Medicine revolution. Penev shares how Edamam's mission to organize the world's food knowledge is leading to a new generation of personalized nutrition tools, including a virtual nutritionist designed to help billions eat better and live longer. Listen for insights on AI innovation, new reimbursement models for nutrition, and why optimism – grounded in data – drives Edamam's next chapter. Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world's biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of our Health Moonshot PRO Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you're mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. » Learn more and apply today. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

Description: Chronic pain can be difficult to live with. If you have psoriatic arthritis you know all too well what that means. Listen as physiatrist Dr. Erin Maslowski and LB Herbert offer ways to manage pain before it manages your life.  Join host Susan McClelland-Tobert, a retired pediatric cardiologist who also lives with psoriatic disease as she uncovers the topic of what is chronic pain and how to manage it with Dr. Erin Maslowski, a physiatrist at Emplify Health System who specializes in physical medicine, rehabilitation and pain management, along with LB Herbert who also lives with psoriasis and psoriatic arthritis, and knows all too well what it means to live with pain, developing her own pain tool kit. Hear different strategies for managing initial flares to when pain escalates. Pain doesn't have to dictate how you live your life.  This episode addresses why pain occurs, it's impact, and what can be done to manage pain both physically and emotionally. Timestamps: (0:23)  Intro to Psoriasis Uncovered & guests physiatrist Dr. Erin Maslowski and LB Herbert (1:48)  The unpredictability of pain and what pain means to LB. (2:31)  The science behind what happens in the body when acute and chronic pain occurs. (5:08)  General principles and first steps to managing pain associated with inflammatory arthritis. (11:00) Recognition of flares and taking action to reduce the impact before pain escalates.        . (14:02) Steps to address the chronic pain cycle as it escalates such as steroid injections and                     medications that change how the brain perceives pain signals. (20:54) Side effects and cautions for use of pain management medications. (24:17) What and who LB turns to for managing her pain. (25:50) Support resources and who to consider as part of a pain management team.   (33:16) Overcoming the stigma of mental health and "it's all in your head". (34:45) Addressing the challenge of fatigue that often comes with pain. It's more than feeling                 tired.  (39:32) Activities to keep the body moving to help avoid stiff joints.          . (42:11) What's on the horizon for managing pain. (44:55) Start small, experiment with change, but above all give yourself grace if you're not able to           do something. Gain what control you can to live your life your way. Key Takeaways: ·       Chronic pain (existing for more than 3 months) occurs when ongoing inflammation keeps signaling pain via the nervous system becoming hypersensitized and greater than the original pain signal. This can occur even when inflammation is managed and in control.   ·       Treating chronic pain is complicated however there are many different avenues to help minimize pain associated with inflammatory diseases such as psoriatic arthritis.   ·       Management of chronic pain involves a variety of specialists and support to help address the         physical and emotional impact of living with chronic pain. Guest Bios: Dr. Erin Maslowski is a board-certified physician, physiatrist, at Emplify Health System where she specializes in Physical Medicine, Rehabilitation, and Orthopedic Sports Medicine providing care for musculoskeletal and spine injuries and pain management including image-guided injection procedures. She has expertise in treating arthritis, spinal stenosis and spondylosis, rotator cuff injury, and other conditions with the ultimate goal of restoring function after injury to the muscle, bone, soft tissue, or nervous system.  Dr. Maslowski is a Clinical Assistant Professor at the University of Wisconsin School of Medicine and Public Health where she teaches both medical students and residents. She has over 15 years of clinical experience in physical medicine and rehabilitation.   LB Herbert, has been living with the challenge of managing pain associated with psoriatic arthritis for 16 years, even developing her own tool kit through the years. She has shared what's she's learned on other episodes of this podcast, through articles, and as a One-to-One Program mentor for the National Psoriasis Foundation. LB began her journey in 2009 with back pain. Following many years of being misdiagnosed she finally found a rheumatologist who put all her symptoms together to diagnose her with psoriatic arthritis and place her on an appropriate treatment path. She states "my biggest challenge is not knowing what each day will bring, what the symptoms will be, and if I wake up and flare. It's a continuous unknown." Resources: Chronic Pain kit  NSAIDS for Psoriatic Disease  Podcast episode: "Living with Chronic with Chronic Pain and Fatigue in PsA and SpA" with rheumatologist Dr. Philip Mease, Dr. Ernest Choy, from Cardiff University School of Medicine, with patients Melissa Leeolou and Minionette "Mini" Wilson who discuss causes, symptoms, risks, and tips for managing chronic pain and fatigue successfully.   

In case you missed it, last week was quite the week in the menopause world. The FDA made a landmark decision to remove all black box warnings from estrogen products and to update the labels of individual products. I was in the room where it all happened and in this episode, I'm going to break it all down for you. But here's the headline- this label change is overall, a good thing, a very good thing. A transcript of this podcast, along with photos and graphics, can be found on DrStreicher.Substack.com In this episode:  A historical perspective of how the Black Box label came to be on all estrogen products A review of the Women's Health Initiative Study  (WHI) that lead to the specific warnings on the label.  The fall out from the release of the WHI The Problems with the Black Box label on estrogen products Class Labeling The difference between oral, transdermal and local vaginal estrogen.  How the required black box label influenced the likelihood of physicians writing a prescription for estrogen, and the likelihood that women would use hormone therapy.  Why I never stopped prescribing estrogen Last week's announcement from the FDA If it is medically appropriate to remove the black box warning from local vaginal estrogen If it is medically appropriate to remove the black box warning from systemic estrogen The inaccurate messaging during the FDA press conference The POLITICS  of WHY the FDA removed the Black Box warnings Related Podcasts:  Episode 124 All Hormones Are Not Created Equal with Dr. James Simon Episode 164 Is Bioidentical Always Best? Episode 181 The FDA Roundtable on Menopausal Hormone Therapy Related Substack Articles Top 20 Questions about Local Vaginal Estrogen Is Bioidentical Always Best? BLOOD CLOTS and ESTROGEN: The Facts Crises at the FDA Why RFK is a Scary Choice for HHS Dr. Streicher is on SUBSTACK      DrStreicher.Substack.com Articles Monthly newsletter All COME AGAIN podcast episodes Monthly News Flash Reports on recent research  Monthly Zoom Ask Me Anything Webinar    Information on Dr. Streicher's COME AGAIN Podcast- Sexuality and Orgasm     Lauren Streicher MD, is a clinical professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, the founding medical director of the Northwestern Medicine Center for Sexual Medicine and Menopause, and a Senior Research Fellow of The Kinsey Institute, Indiana University. She is a certified menopause practitioner of The Menopause Society. S   Dr. Streicher is the medical correspondent for Chicago's top-rated news program, the WGN Morning News, and has been seen on The Today Show, Good Morning America, The Oprah Winfrey Show, CNN, NPR, Dr. Radio, Nightline, Fox and Friends, The Steve Harvey Show, CBS This Morning, ABC News Now, NBCNightlyNews,20/20, and World News Tonight. She is an expert source for many magazines and serves on the medical advisory board of The Kinsey Institute, Self Magazine, and Prevention Magazine. She writes a regular column for The Ethel by AARP and Prevention Magazine.    LINKS Subscribe To Dr. Streicher's Substack Information About the COME AGAIN Podcast Dr. Streicher's CV and additional bio information To Find a Menopause Clinician and Other Resources  Glossary Of Medical Terminology Books by Lauren Streicher, MD    Slip Sliding Away: Turning Back the Clock on Your Vagina-A gynecologist's guide to eliminating post-menopause dryness and pain Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Sex Rx- Hormones, Health, and Your Best Sex Ever The Essential Guide to Hysterectomy                                        Dr. Streicher's Inside Information podcast is for education and information and is not intended to replace medical advice from your personal healthcare clinician. Dr. Streicher disclaims liability for any medical outcomes that may occur because of applying methods suggested or discussed in this podcast.                                     

20201 Vital Plan & Coffee for Heart Health Podcast | Dare To Be Vital BookFIVE PRIMARY POINTS of the PODCAST1. Vitamin D Dramatically Reduces Heart Attack RiskNew American Heart Association data shows that maintaining vitamin D levels >40 ng/mL for ~4 years cuts recurrent heart attack risk by 52%. Most participants required 5,000 IU/day—far above the current FDA recommendation—to reach optimal levels, making vitamin D testing and personalized supplementation a critical and cost-effective intervention.2. Structured Exercise Improves Cancer SurvivalA large randomized trial in colorectal cancer patients found 90% survival with structured exercise vs. 83% with health education alone (a 42% relative reduction in mortality). Supervised and behaviorally supported exercise—not just information—is required to produce this survival advantage.3. Exercise Should Be Prescribed as Medicine for Cancer PatientsThe transcript highlights mechanisms—myokines, reduced inflammation, better fitness, and increased natural killer cell activity—that explain why exercise reduces cancer mortality. Recommendation: oncologists should prescribe personalized strength and fitness programs as part of cancer care.4. Exercise Is One of the Most Powerful Sleep OptimizersA study of 380 medical students showed:* Low physical activity = poor sleep quality* Being overweight or stressed worsens sleep* Strength training is the most effective exercise modality for improving sleep.The message: Use movement—especially strength training—to break the “doom loop” of poor sleep and inactivity.5. Vitality Is a Skill: Small Daily Choices CompoundThe episode reinforces two overarching themes:* Vitality is a skill you can learn, practice, and improve.* Vitality powers performance—especially through the synergy of exercise, sleep, vitamin D, strength, and connection.The weekly action: Get your vitamin D level checked and optimize it with guidance from your doctor.Copyright VyVerse LLC, All Rights Reserved This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit vitalityexplorers.substack.com/subscribe

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

In this episode of The Spine Pod, hosts Courtney Schutze and Brady Riesgraf sit down with Dr. Kamal Woods, a double fellowship-trained surgeon in both orthopedics and neurosurgery, and founder of Vertrae® in Miamisburg, Ohio.   Dr. Woods received his medical degree from Loma Linda University School of Medicine and completed a fellowship in minimally invasive and complex spine surgery from Cedars‑Sinai Medical Center. He later earned his MBA from Johns Hopkins Carey Business School, further deepening his understanding of the complex healthcare ecosystem and how to improve it. Since then, he has gone on to build a patient-centered practice rooted in the belief that one size does not fit all when it comes to spine care. Whether a patient needs a non‑surgical treatment, minimally invasive surgery, or motion‑preserving option, the goal remains the same: restore mobility, alleviate pain, and help patients return to what they love most.   Throughout the episode, Dr. Woods shares his philosophy of combining surgical precision with compassionate, personalized care. He also discusses the importance of having a full “toolbox” of treatments, from conservative care and robotic‑assisted techniques to artificial disc replacement, and why patient education and shared decision‑making are essential. He goes on to share how his background, far from conventional, has shaped his patient‑first mindset and his vision for modern spine care.   In this episode, you'll learn: Why motion preservation is more than a trend, it's about protecting function and long-term quality of life. How insurance and reimbursement barriers can impact patient care, and the changes needed to move the field forward. Why outpatient, motion-preserving spine care is gaining momentum and what it takes to build a successful model. How Dr. Woods prioritizes patients through individualized treatment plans for those dealing with chronic leg and back pain. Why enabling technologies such as navigation and robotics are expanding into more surgical facilities. How Vertrae® is driving local innovation through education, community events, and an empowering patient-centered care model.   Drawing on his childhood roots in Saint Vincent, his surgical training in California, and the practice he's built in Ohio, Dr. Woods is shaping an innovative spine care model centered on motion preservation—designed to help patients return to the activities they love, all in one integrated setting. Whether you're a surgeon focused on emerging technologies, an industry professional tracking care trends, or a patient seeking clarity in a crowded spine landscape, this episode delivers compelling insights on how treatment pathways are shifting and how modern practice models are evolving.   Learn more about Dr. Woods: Vertrae: https://vertrae.com/ LinkedIn: https://www.linkedin.com/in/kamal-woods-md-mba-89172682/ Instagram: https://www.instagram.com/vertrae.inc/?hl=en Facebook: https://www.facebook.com/KamalWoodsMD YouTube: https://www.youtube.com/ ⁨@vertrae360⁩   You can find The Spine Pod on all Podcast Streaming Platforms, including: YouTube: https://www.youtube.com/@TheSpinePod Spotify: https://open.spotify.com/show/0DBzWfVt1ExQE0qTjhOERa?si=EEBPwQgRQSujyZsaXnJagA Apple Podcasts: https://podcasts.apple.com/us/podcast/the-spine-pod/id1745442311 Amazon Music: https://music.amazon.com/podcasts/98fd41ad-75ee-4371-bb70-c5b274324a47/the-spine-pod?ref=dm_sh_kmfvSHB5iY109GDslhiJul22E iHeart Radio: https://www.iheart.com/podcast/269-the-spine-pod-174320414?cmp=ios_share&sc=ios_social_share&pr=false&autoplay=true Follow The Spine Pod to learn more about the latest episodes and happenings in the world of motion preservation: ⁠ Facebook: https://www.facebook.com/profile.php?... Instagram: https://www.instagram.com/thespinepod... TikTok: www.tiktok.com/@thespinepod The information in this podcast is for educational and informational purposes only and is not intended as medical advice.

Today I'm thrilled to host Dr. Kyle Fortinsky, an early to mid-career gastroenterologist in Ontario.Kyle and I share something in common - we deeply value our time and the ability to spend it with our families.With this in mind, Kyle co-founded Clever Consult - an AI-enabled software helping specialists automate and streamline the consultation process, saving many hours along the way.Join me as I dig into Kyle's entrepreneurial journey, unpacking lessons for everyone along the way.Discussion points:Kyle's introduction (1:40)Understanding Clever Consult (4:35)- basics, target audience, EMR integration, time savingsLearning through feedback (19:45)What it's like to build a company (23:12)Letting go of things to free up time (28:05)Lessons from an MBA (29:35)What would Kyle have done differently? (32:19)What did Kyle learn about himself? (35:45)Ideal split between clinical medicine & entrepreneurship (38:10)Advice to someone considering starting something (40:12)Kyle Fortinsky:Clever Consult: https://www.cleverconsult.ai/Yatin Chadha:website: https://www.beyondmd.ca/LinkedIn: https://www.linkedin.com/in/yatin-chadha/Amex referral: https://americanexpress.com/en-ca/referral/business-platinum?ref=yATINCnPBE&XLINK=MYCP

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients'.

Send us a textIn this episode of Going Under: Anesthesia Answered, Dr. Brian Schmutzler and Vahid Sadrzadeh go into outer space.What would it really take to deliver safe anesthesia in orbit? Blending new microgravity research with practical anesthesiology to map the risks, the tools, and the best‑bet strategies for keeping a patient stable when everything floats.If you're curious about space medicine, anesthesiology, or how frontier research translates into better everyday care, this conversation lays out the emerging playbook. Have a question for Dr. Brian Schmutzler? Submit them to any of the social media pages below or on his website at https://www.drbrianschmutzler.com/Facebook: https://www.facebook.com/drbrianschmutzlerInstagram: https://www.instagram.com/drbrianschmutzlerTikTok: https://www.tiktok.com/@drbrianschmutzler?lang=enProvider or Medical Student?? Subscribe to his Patreon Page to get exclusive content and access to Medical Blocks:https://www.patreon.com/user?u=89356957&utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=creatorshare_creator&utm_content=join_linkThanks to our show sponsor: Butterfly Networkhttps://store.butterflynetwork.com/us/en/?rsCode=BRIAN25You can get $750 off the latest IQ3. Check it out at ButterflyNetwork.comSupport the show

Janette Hope, MD, FAAEM, DABEM, DABFM, is a board certified family practitioner who has also completed the training and certification requirements to become a diplomate and in the fields of Environmental Medicine with certification through the American Board of Environmental Medicine in 2011 and in Integrative Medicine through the American Board of Physician Specialties affiliated  American Board of Integrative Medicine in 2016.   In this insightful discussion, Dr. Osborne and Dr. Hope explore the often-overlooked issue of mold exposure in medical training and practice. Dr. Hope shares her personal journey of discovering mold's impact on health after experiencing symptoms herself, highlighting a significant gap in medical education regarding mold-related illnesses. Dr. Hope emphasizes the importance of recognizing mold exposure and its long-term effects on patients, advocating for better awareness among clinicians and patients alike. Dr. Osborne and Dr. Hope discuss the challenges of diagnosing mold-related health issues, the necessity of environmental assessments, and the psychological aspects of recovery. The conversation underscores the need for healthcare providers to support patients through their healing process, as many may experience heightened reactions after leaving moldy environments.For more on Dr. Janette Hope, visit: https://janettehopemd.com/Gluten Sensitive?  Take the quiz & Join Our Community ▶https://www.glutenfreesociety.org/gluten-sensitivity-intolerance-self-test/Get my quick start guide on going gluten free: https://www.glutenfreesociety.org/how-to-go-gluten-free/Nutritional Crash Courses Playlist: https://www.glutenfreesociety.org/nutritionGet Gluten Free Supplements: https://www.glutenfreesociety.org/shop-home/No Grain No Pain the Book: https://www.glutenfreesociety.org/NoGrainNoPainGlutenology Masterclass (Ultimate Guide): https://glutenology.net/registrationTo connect with Dr. Osborne visit:On the web: https://drpeterosborne.com/Facebook: https://www.facebook.com/DoctorPeterOsborne/TikTok: https://www.tiktok.com/@drpeterosborneInstagram: https://www.instagram.com/drosborneTwitter: https://twitter.com/glutenologyPinterest: https://www.pinterest.com/docosborne/Podcast:Apple Podcasts: https://podcasts.apple.com/us/podcast/dr-osbornes-zone/id1706389688?uo=4Spotify: https://open.spotify.com/show/4Zdf07GgpRAVwlSsYvirXTAmazon Music/Audible: https://music.amazon.com/podcasts/20d71b2e-3554-4569-9d5b-4259785cdc94Google Podcasts: https://www.google.com/podcasts?feed=aHR0cHM6Ly93d3cuc3ByZWFrZXIuY29tL3Nob3cvNTkwNjcwNC9lcGlzb2Rlcy9mZWVkiHeart Radio: https://iheart.com/podcast/119388846Dr. Peter Osborne is one of the most sought after alternative and nutritional experts in the world. A Diplomate with the American Clinical Board of Nutrition, a graduate of Texas Chiropractic College, and a doctor of pastoral science, Dr. Osborne is one of the world's leading authorities on gluten, nutrition, and natural health.   He is the founder GlutenFreeSociety.org, one of the world's largest informational sites on gluten sensitivity.  In addition, he is the author of the best selling book, No Grain No Pain, published by Touchstone (Simon & Schuster).  His work has been featured by PBS, Netflix, Amazon, Fox, U.S. News, Ney York Post, and many other nationally recognized outlets.For collaborations please email: glutenology@gmail.comAny information on diseases, treatments, nutrition, or other health related topics from this channel are for educational purposes only, and should not be considered a substitute for advice provided by your doctor or healthcare provider.  Bottom line...if you have health issues, you should always seek professional medical guidance.Products and supplements discussed in this video have not been evaluated by the FDA.  They are not intended to treat, cure, or diagnose.  Dr. Osborne is an Amazon affiliate, and many earn from qualifying purchases.   For more information, visit us at https://www.glutenfreesociety.org/  or call 281-903-7527

The most alive wisdom often waits at the edge where things end. We step onto the threshold between astrology's eighth and ninth houses with Dr. Travis Elliott, a naturopath who traded protocols for presence and found his way into Asclepian dream healing, plant medicines, and the kind of listening that lets the body speak. This conversation travels from Santa Fe's Living Astrologies conference to the old temples where snakes curled at our feet, and into the myths where Asclepius learns from Chiron, Coronis vanishes into smoke, and Medusa's two vials test how far we'll go to outwit death.We talk about what happens when healthcare stops treating people like problems and starts treating symptoms as messages. Travis shares how an image can surface in the room—a felt priority that guides the next step—and how clients reclaim agency when they learn to sit with what hurts. Along the way, we unpack the eighth house as a place of composting and grief, the ninth house as the clear sky of meaning, and Ophiuchus as the healer who stands between them. We look at diurnal motion versus zodiacal motion, Telesphorus as the small herald of completion, and the moment when pushing against death breaks the order that keeps life and underworld in balance.Underneath the astrology is a simple invitation: stay with the darkness until it's done with you, then rise with meaning that is yours. If you've been craving a more soulful healthcare—one that respects intuition, the feminine, and the earth's timing—this is a map back to that remembering. Listen, share it with a friend who needs permission to slow down, and if it resonates, subscribe and leave a review so more people can find the work. *The above blurb was produced by Buzzsprout's AI.Join the Newsletter! Podcast Musician: Marlia CoeurPlease consider becoming a Patron to support the show!Go to OnTheSoulsTerms.com for more.

What if just 40 seconds of genuine compassion could tangibly lower a cancer patient's anxiety—and what if this "wonder drug" holds the key not just for healthcare, but for every leader who wants to create more fulfilling workplaces and customer experiences? The impact of this question is profound. On this episode of the Delighted Customers podcast, I sat down with Dr. Stephen Trzeciak ("Dr. T"), whose groundbreaking research proves that compassion isn't just good for our conscience—it's scientifically measurable, essential, and transformative for both the receiver and the giver. Whether you lead a care team, a corporate department, or simply want more meaning in your professional interactions, Dr. T's work illustrates how compassion can drive loyalty, improve outcomes, and even keep your best people from walking out the door. You should listen to Dr. T because his expertise bridges the gap between touching stories and hard data. With two acclaimed books—Compassionomics and Wonder Drug—plus clinical leadership at the front lines of healthcare, Dr. T demonstrates how compassion delivers ROI. He shares evidenced-based tactics any leader can use to operationalize compassion, strengthen teams, and create unforgettable customer moments—even in high-stress, time-pressured environments. Here are three compelling questions Dr. T answers on this episode: How can business leaders operationalize compassion without losing authenticity or making it "just another initiative"? What simple, proven behaviors can leaders implement today to measurably improve compassion in their teams? What's the REAL ROI of building a compassionate culture, and how can you quantify its impact to win executive buy-in? If you're ready to transform the way you serve customers—and keep your teams thriving—listen and subscribe to the Delighted Customers podcast now! Find us on Apple Podcasts and Spotify. We're available on all your favorite podcast platforms. Meet Dr. Stephen Trzeciak ("Dr. T") Dr. Stephen Trzeciak is a physician scientist, intensive care doctor, and the Chief of Medicine at Cooper University Health Care in Camden, New Jersey. He is Professor and Chair of Medicine at Cooper Medical School of Rowan University. With over two decades of clinical and research experience, Dr. T is renowned for his work in linking compassion with improved clinical outcomes and the science behind "Compassionomics." He's co-authored two widely acclaimed books: Compassionomics: The Revolutionary Scientific Evidence that Caring Makes a Difference and Wonder Drug: 7 Scientifically Proven Ways that Serving Others is the Best Medicine for Yourself. His TEDx talks and keynote appearances have inspired audiences worldwide, urging leaders inside and outside healthcare to harness the measurable power of serving others. Dr. T's research focuses on the biological effects of compassion (on both patients and care providers), strategies for building compassionate cultures, and proven methodolgies for measuring and teaching compassion. He is passionate about helping organizations—from hospitals to global corporations—improve their outcomes by focusing on the human dimension of care and leadership. Connect with Dr. T on LinkedIn. Show Notes & References Compassionomics: The Revolutionary Scientific Evidence that Caring Makes a Difference Wonder Drug: 7 Scientifically Proven Ways Serving Others Is the Best Medicine for Yourself Study: "The Power of 40 Seconds" and compassion intervention research (Journal of General Internal Medicine) JAMA Psychiatry study on compassion phone interventions for loneliness in elderly populations Gallup Report: What Followers Want From Leaders (2025) McKinsey & Company Research on Attrition in Healthcare Dr. T's LinkedIn Podcast on Apple Podcast on Spotify

Morning Show 11-20-25 Hour 2 Rev Cummings--Dr Tarkin, WVU Medicine by The Watchdog

I've seen so many patients struggle with fatigue, brain fog, and burnout, and this conversation gave me a new way of thinking about why that happens and how to approach it. On this episode of The Dr. Hyman Show, I'm joined by Dr. Martin Picard, a Columbia scientist studying how energy flows through the body, and what that flow means for how we think, feel, and age. We touch on a simple idea that could reframe the way you understand your own energy, and how your daily choices influence it over time. Catch the full conversation on YouTube or listen wherever you get your podcasts. We uncover: • Why your energy can feel “off” even when labs look normal • What mitochondria communicate beyond just ATP production • How stress, recovery, and sleep shift your cellular energy capacity • Why individuality matters more than group averages in real life health outcomes • The simple daily choices that build or drain metabolic resilience over time At the end of the day, energy is the foundation of how we show up in our lives, and we can influence it more than we think. Resources on the blog: • Phenomics and the Energy Resistance Principle  View Show Notes From This Episode Get Free Weekly Health Tips from Dr. Hyman https://drhyman.com/pages/picks?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Sign Up for Dr. Hyman's Weekly Longevity Journal https://drhyman.com/pages/longevity?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Join the 10-Day Detox to Reset Your Health https://drhyman.com/pages/10-day-detox Join the Hyman Hive for Expert Support and Real Results https://drhyman.com/pages/hyman-hive This episode is brought to you by Seed, Pique, Function Health, Paleovalley, PerfectAmino and Big Bold Health. Visit seed.com/hyman and use code 20HYMAN for 20% off your first month of Seed's DS-01® Daily Synbiotic. Receive 20% off FOR LIFE + a free Starter Kit with a rechargeable frother and glass beaker at Piquelife com/Hyman. Join today at FunctionHealth.com/Mark and use code HYMAN100 to get $100 toward your membership. Get nutrient-dense, whole foods. Head to paleovalley.com/hyman for 15% off your first purchase. Go to bodyhealth.com and use code HYMAN20 for 20% off your first order.Get 20% off HTB Immune Energy Chews at bigboldhealth.com and use code DRMARK20.

Dr. Leonard Weinstock discusses Innovative Solutions for Mast Cell Activation Syndrome with Dr. Ben Weitz.   [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]    Podcast Highlights           Dr. Leonard Weinstock is Board Certified in Gastroenterology and Internal Medicine, practicing in St. Louis, Missouri.  He is president of Specialists in Gastroenterology and the Advanced Endoscopy Center.  He teaches at Barnes-Jewish Hospital and is an Associate Professor of Clinical Medicine and Surgery at Washington University School of Medicine. Dr. Weinstock is an active lecturer, including having spoken at some SIBO conferences, and he has published more than 70 articles, editorials, and book chapters.  He has teamed with Dr. Lawrence Afrin to research and publish articles on Mast Cell Activation syndrome and gastroenterology.  His contact info is at Specialists in Gastroenterology and his phone is 314-997-0554. Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.  

European Study of Prostate Cancer Screening — 23-Year Follow-upAssociation Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure–Lowering TherapyFurther Reading* Effects of intensive blood-pressure control in type 2 diabetes mellitus* A Randomized Trial of Intensive versus Standard Blood-Pressure ControlSensible Medicine is 100% reader-supported. If you appreciate our work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

This week, we look at new research on potassium optimization in patients with defibrillators, reducing antihypertensive therapy in nursing homes, an mRNA influenza vaccine, and belzutifan for rare neuroendocrine tumors. We review long QT syndrome and present a case of abnormal behavior and seizures in a young man. We also explore perspectives on primary care reform, tobacco cessation in HIV and tuberculosis care, corporate control in health care, and the simple power of compassion with ice cream.

Dr. Hoffman continues his conversation with clinical pharmacist, author, board-certified clinical nutritionist, and health expert Jim LaValle on the many health benefits of aged garlic extract.

Clinical Pharmacist, Author, Board-Certified Clinical Nutritionist, and Health Expert Jim LaValle details the many health benefits of aged garlic extract, particularly its impact on periodontal disease. He reveals exciting new research findings that show Kyolic Aged Garlic Extract supplements can significantly reduce periodontal pocket depth -- a key indicator of gingivitis and periodontal disease progression. He also highlights the role of aged garlic extract in reducing inflammation and improving gum health, which in turn has significant implications for cardiovascular and cognitive health. The conversation also touches on various formulations of aged garlic extract available from Kyolic, the importance of integrative approaches to health and wellness, and updates on the latest trends in anti-aging medicine, including peptides and GLP-1 agonists.

This special episode of Unfiltered departs from its usual cadence and lineup as cardiologist Jonathan Fisher is joined this week by his wife, oncologist Dr. Julie Fisher. Together with hosts ... The post FHC #195: Dr. Julie Fisher on medicine, marriage & misogyny appeared first on Fixing Healthcare.

  NM takes lead to investigate forced sterilization of women   Native vote, lifetime achievement awards take center stage at NCAI  

Dr. Maria Janakos is a sports medicine physiatrist at NYU and a Clinical Assistant Professor at the NYU Grossman School of Medicine. She completed her residency at the University of Louisville and a Primary Care Sports Medicine Fellowship at Morristown Medical Center in New Jersey. Her clinical interests include concussion management, orthobiologics, musculoskeletal ultrasound, and event coverage. Dr. Janakos is actively involved in medical education at NYU, teaching medical students, residents, and fellows through lectures, hands-on training, and mentorship. At NYU, she is an active member of the NYU Concussion Center, where she regularly lectures on various concussion topics at both local and national levels. She specializes in the care of patients with acute concussions, treating individuals from adolescence through age 45. Part 2 The discussion included the following topics: challenges that patients face during the recovery period; factors determining treatment outcomes; preventing concussions; composition of the interdisciplinary treatment team; and the role of technology in treatment interventions.    

Today, on Notable Leaders' Radio, I speak with Jourdan Hathaway, Chief Business Officer of the General Assembly. She emphasizes how resilience, courage, and the willingness to ask for help have been key in her transition from a childhood of poverty to a successful executive leader.  In today's episode, we discuss: Reflect on the childhood influences that shaped you and your future aspirations. Jourdan shares how her experience growing up in extreme poverty shaped her early dream of working in advertising, inspired by the TV show "Bewitched." That dream became a guiding star through hardship. Create your own learning path to fill critical gaps. When promoted to a leadership role outside her area of expertise, Jourdan built Project FLAT: Financial Literacy Advancement Training to master finance through journaling, mentorship, and resilience quickly. Cultivate resilience as a core leadership skill. Jourdan's story illustrates how bouncing back from setbacks and persisting despite obstacles is essential for long-term success and impact. Define leadership through vulnerability and empathy. Jourdan explains how her acronym DRIVEN (determined, resilient, impactful, vulnerable, empathetic, nimble) reflects her belief that true leadership includes asking for help and lifting others up. RESOURCES: Guest Bio Jourdan Hathaway is Chief Business Officer at General Assembly, a global leader in talent development and upskilling. She oversees marketing, sales enablement, client delivery, admissions, student experience, career services, alumni relations, and partnerships. Jourdan's journey spans agency marketing to edtech, blending operational excellence with a passion for building inclusive, future-ready organizations. She is recognized for strategic leadership, business growth, and talent transformation, and serves as a mentor and member of the Exceptional Women Alliance.   Website/Social Links www.GA.co https://www.linkedin.com/in/jourdan-hathaway Belinda's Bio: Belinda is a sought-after Leadership Advisor, Coach, Consultant, and Keynote speaker and a leading authority in guiding global executives, professionals, and small business owners to become today's highly respected leaders. As the Founder of BelindaPruyne.com, Belinda works with organizations such as IBM, Booz Allen Hamilton, BBDO, The BAM Connection, Hilton, Leidos, Yale School of Medicine, Landis, Portland Trail Blazers, and the Discovery Channel. Most recently, she redesigned two global internal advertising agencies for Cella, a leader in creative staffing and consulting. She is a founding C-suite and executive management coach for Chief, the fastest-growing executive women's network. Since 2020, Belinda has conducted over 120 interviews with top-level executives and business leaders, who share their personal journeys to success, revealing the truth about what it took to achieve their success on her Notable Leaders Radio podcast. She gained a wealth of expertise in the client services industry as Executive Vice President and Global Director of Creative Management at Grey Advertising, managing over 500 people worldwide. With over 20+ years of leadership development experience, she brings industry-wide recognition to the executives and companies she works with. Whether a startup, turnaround, acquisition, or global corporation, executives and companies continue to turn to Pruyne for strategic and impactful solutions in a rapidly shifting economy and marketplace. Website: Belindapruyne.com Email Address: hello@belindapruyne.com LinkedIn: https://www.linkedin.com/in/belindapruyne  Facebook: https://www.facebook.com/NotableLeadersNetwork.BelindaPruyne/  Twitter: https://twitter.com/belindapruyne?lang=en  Instagram: https://www.instagram.com/belindapruyne/  Surround yourself with experienced mentors. From public speaking training to business skills, Jourdan emphasizes that growing into leadership is a journey supported by those who have already walked the path.  

In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Joseph Leventhal, Professor of Surgery and Director of Living Donor Kidney Transplantation at Northwestern University Feinberg School of Medicine. A pioneer in the field of organ transplantation, Dr. Leventhal's research is redefining what's possible in immune tolerance—an area often described as the “holy grail” of transplantation, where a patient's body can accept a donated organ without lifelong immunosuppressive drugs.Dr. Leventhal shares his journey from growing up in New York City to becoming one of the foremost leaders in transplant surgery and cell therapy innovation. He discusses how his team's groundbreaking clinical work has shown that tolerance can be achieved through cellular therapies, potentially freeing patients from the burdens of chronic immunosuppression.From the early days of cyclosporine to founding TRACT Therapeutics and developing first-in-human T-regulatory cell therapies, Joe reflects on the scientific curiosity, resilience, and collaboration that drive progress in a complex field. He also explores the evolving ecosystem for biotech innovation in Chicago, the challenges of translating academic research into clinical therapies, and the optimism surrounding the next generation of precision cell therapies.

Proteins are crucial for life. They're made of amino acids that “fold” into millions of different shapes. And depending on their structure, they do radically different things in our cells. For a long time, predicting those shapes for research was considered a grand biological challenge.But in 2020, Google's AI lab DeepMind released Alphafold, a tool that was able to accurately predict many of the structures necessary for understanding biological mechanisms in a matter of minutes. In 2024, the Alphafold team was awarded a Nobel Prize in chemistry for the advance.Five years later after its release, Host Ira Flatow checks in on the state of that tech and how it's being used in health research with John Jumper, one of the lead scientists responsible for developing Alphafold.Guest: John Jumper, scientist at Google Deepmind and co-recipient of the 2024 Nobel Prize in chemistry.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

 Today we unpack a groundbreaking new study showing exercise stops cancer from coming back after treatment. We also talk about what really matters for building strength and longevity, how to know if you're actually gaining muscle, and which labs are worth asking for at your next physical. Spoiler: “toning” isn't a thing, but progressive overload definitely is. Timestamps:[1:35] Welcome[15:15] Discussion about study on how exercise is better than drugs to stop cancer[29:11] What are the top 3 basics for fitness after age 35?[42:15] I'm due for a physical and I want bloodwork and don't know what to ask for. [49:05] I've been lifting more intentionally, but not sure if what I'm doing is building muscle. How do I know if I'm building muscle vs. maintaining? Episode Links:Exercise ‘better than drugs' to stop cancer returning after treatment, trial findsNoelle's instagram post: Exercise is more effective than drugs at stopping cancerSponsors:Go to https://thisisneeded.com/  and use coupon code WELLFED for 20% off your first order.Go to curednutrition.com/wellfed and use code WELLFED for 20% off.Go to http://mdlogichealth.com/chocolate and use coupon code COLLAGEN15  for 15% off.Go to boncharge.com/WELLFED and use coupon code WELLFED to save 15% off any order.